ClinicalTrials.gg
TerminatedNCT02862431Updated Apr 27, 2025

Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)

A Phase 1 interventional study of JNJ-64565111 and Placebo in Diabetes Mellitus, Type 2, sponsored by Janssen Research & Development, LLC. Terminated at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Why this study was terminated
manufacturing-related issues

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Johnson & Johnson.

Enrollment
48th of 54
24 · median 115
Started
2016
with 3 others
Phase 1
21 of 62
none open now
Registered
55th of 62
by date

Among the 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson, this one is the 48th largest by enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2016, is one of 21 in phase 1, and was the 55th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of JNJ-64565111 in adult Men and Women (of non-child bearing potential) with Type 2 Diabetes Mellitus.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Type 2 Diabetes Mellitus (T2DM) at least 3 months prior to Screening
  • On a stable treatment regimen at least 3 months prior to Screening of (1) diet and exercise, or (2) metformin monotherapy (at a dose of at least 1,000 milligram (mg) per day)
  • Blood pressure between 90 and 140 millimeter of mercury (mmHg) systolic, inclusive, and between 60 and 100 mmHg diastolic, inclusive at Screening (sitting) and Day -2 (supine). If blood pressure is out of range, up to 2 repeated assessments are permitted
  • greater than or equal to 6.5% and less than 8.5% at Screening
  • Females of non-

Exclusion criteria

Exclusion Criteria:

  • History of, or currently active, significant illness or medical disorders, including cardiovascular disease (including cardiac arrhythmias, myocardial infarction, stroke, peripheral vascular disease), hematological disease (example, von Willebrand's disease or other bleeding disorders), respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmologic disorders, neoplastic disease, skin disorder, renal disorder, or any other illness that the Principal Investigator (PI) considers should exclude the participant or that could interfere with the interpretation of the study results
  • Previous surgical treatment for obesity (example, gastric bypass, gastric banding)
  • History of diabetic neuropathy with signs of gastroparesis and/or known proliferative retinopathy or maculopathy
  • History or current diagnosis of acute or chronic pancreatitis
  • History of an invasive cardiovascular surgical procedure including, but not limited to, coronary artery bypass graft (CABG), or percutaneous coronary intervention (PCI)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort 1 (JNJ-64565111 2.5 nmol/kg or Placebo)

    Participants in ratio of 3:1 will receive 2.5 Nanomole Per Kilogram (nmol/kg) JNJ-64565111 or placebo.

    Drug: JNJ-64565111 · Drug: Placebo

  • Experimental
    Cohort 2 (JNJ-64565111 3 nmol/kg or Placebo)

    Participants in ratio of 3:1 will receive 3.0 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.

    Drug: JNJ-64565111 · Drug: Placebo

  • Experimental
    Cohort 3 (JNJ-64565111 3.5 nmol/kg or Placebo)

    Participants in ratio of 3:1 will receive 3.5 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.

    Drug: JNJ-64565111 · Drug: Placebo

  • Experimental
    Cohort 4 (JNJ-64565111 Repeat or Lower Dose or Placebo)

    Participants in ratio of 3:1 will receive a dose of JNJ-64565111 or placebo that would be a repeat or lower dose level previously assessed as well-tolerated.

    Drug: JNJ-64565111 · Drug: Placebo

Interventions

  • Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.

  • DrugPlacebo

    Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability

    Time frame: Up to Day 72

Secondary outcomes

  1. Number of Participants With Incidence of Anti-JNJ-64565111 Antibodies as Measure of Immunogenicity

    Time frame: Up to Day 72

  2. Change From Baseline in Body Weight

    Time frame: Baseline, up to Day 72

  3. Maximum Observed Plasma Concentration (Cmax)

    Maximum observed plasma concentration (Cmax) will be assessed after first dose and last dose.

    Time frame: Up to Day 72

  4. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Tmax defined as actual sampling time to reach maximum observed analyte concentration will be assessed after first dose and last dose.

    Time frame: Up to Day 72

  5. Area Under Concentration from time zero to the last quantifiable concentration AUC(0-last)

    AUC from time zero to the last quantifiable concentration will be assessed after first dose and after last dose.

    Time frame: Up to Day 72

  6. Area Under Curve over the dosing interval AUC(0-tau)

    The AUC \[0-tau\] is the measure of the plasma drug concentration from time zero to end of dosing interval. It is used to characterize drug absorption. AUC \[0-tau\] will be assessed after first dose and last dose.

    Time frame: Up to Day 72

  7. Elimination Half-Life (t1/2)

    The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. t1/2 will be assessed after first dose and last dose.

    Time frame: Up to Day 72

  8. Apparent Clearance (CL/F)

    The Oral Clearance (CL/F) is the clearance based on oral bioavailability. CL/F will be assessed after first dose and last dose.

    Time frame: Up to Day 72

  9. Apparent Volume of Distribution (V/F)

    Apparent volume of distribution will be assessed after first dose and last dose.

    Time frame: Up to Day 72

  10. Terminal Rate Constant (K)

    Terminal rate constant will be assessed after first dose and last dose.

    Time frame: Up to Day 72

  11. Average concentration over the dosing interval at steady state (Caverage,ss)

    The average concentration over the dosing interval at steady state, calculated as AUC(0-tau)/tau and will be assessed after last dose.

    Time frame: Up to Day 72

  12. Minimum Observed Plasma Concentration (Cmin)

    The Cmin is the minimum observed plasma concentration over the dosing interval at steady state. Cmin will be assessed after last dose.

    Time frame: Up to Day 72

  13. Area Under Curve from time zero extrapolated to infinity AUC(0-inf)

    AUC from time zero extrapolated to infinity will be assessed after last dose.

    Time frame: Up to Day 72

  14. Accumulation Ratio

    Accumulation ratio calculated as AUC(0-tau), Day 22 / AUC(0-tau), Day 1 will be assessed after last dose.

    Time frame: Up to Day 72

  15. Change From Baseline in Blood Pressure

    Time frame: Baseline, up to Day 72

  16. Change From Baseline in Heart Rate

    Time frame: Baseline, up to Day 72

  17. Change From Baseline for 24-hour Mean Plasma Glucose

    Mean plasma glucose defined as the total and/or incremental area under the concentration (AUC) time curve over 0 to 24 hours, divided by 24.

    Time frame: Baseline, Day 26

  18. Change From Baseline in Fasting Plasma Glucose (FPG)

    Time frame: Baseline, up to Day 72

  19. Change From Baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline, up to Day 72

  20. Change From Baseline on Fasting Lipids

    Total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), very low-density lipoprotein cholesterol (VLDL-C), triglycerides and free fatty acids will be reported.

    Time frame: Baseline, up to Day 72

  21. Change From Baseline in Insulin Secretion

    Time frame: Baseline, Day 26

  22. Change From Baseline in Insulin Sensitivity

    Time frame: Baseline, Day 26

  23. Change From Baseline for C-peptide

    Time frame: Baseline, Day 26

  24. Change From Baseline for Glucagon

    Time frame: Baseline, Day 26

07

Study locations

1 site
  • Neuss, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Nov 2016, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2016
First posted
Aug 11, 2016
StartActual
Jul 12, 2016
Primary completionActual
Nov 29, 2016
CompletionActual
Dec 5, 2016
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02862431
Responsible party
Sponsor
First posted
Aug 11, 2016
Start date
Jul 12, 2016
Primary completion
Nov 29, 2016
Completion
Dec 5, 2016
Last update
Apr 27, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efinopegdutide

Start the discussion